Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01626339
Recruitment Status : Unknown
Verified June 2012 by University of Malaya.
Recruitment status was:  Recruiting
First Posted : June 22, 2012
Last Update Posted : June 22, 2012
Information provided by (Responsible Party):
University of Malaya

Brief Summary:

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Condition or disease Intervention/treatment Phase
Age Related Macular Degeneration Drug: Intravitreal Ranibizumab Drug: Intravitreal bevacizumab Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Official Title: Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter
Study Start Date : April 2012
Estimated Primary Completion Date : June 2012

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Intravitreal Ranibizumab
    Other Name: Lucentis
  • Drug: Intravitreal bevacizumab
    Other Name: Avastin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease

Exclusion Criteria:

  • History of previous systemic or ocular Anti-VEGF therapy
  • History of previous intravitreal injection with any drug
  • Intraocular pressure ≥ 22
  • Glaucoma
  • History or presence of thromboembolic events
  • Un-controlled blood pressure
  • Blood donation during the previous 3 weeks
  • Relevant media opacity of the lens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01626339

Contact: Mohammadreza Peyman, MD 0060173387260 ext 1
Contact: Visvaraja Subrayan, Prof

University of Malaya Medical Center Recruiting
Kuala Lumpur, Malaysia, 59100
Contact: Mohammadreza Peyman, MD    0060173387260   
Sponsors and Collaborators
University of Malaya

Responsible Party: University of Malaya Identifier: NCT01626339     History of Changes
Other Study ID Numbers: PPUM/MDU/300/04/03
First Posted: June 22, 2012    Key Record Dates
Last Update Posted: June 22, 2012
Last Verified: June 2012

Keywords provided by University of Malaya:
Anti vascular endothelial growth factor
retinal vessels

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Endothelial Growth Factors
Glucuronyl glucosamine glycan sulfate
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Immunologic Factors
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Hypoglycemic Agents